Humankind Investments LLC Has $1.56 Million Position in Amgen Inc. (NASDAQ:AMGN)

Humankind Investments LLC grew its holdings in Amgen Inc. (NASDAQ:AMGN - Free Report) by 20.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 5,985 shares of the medical research company's stock after purchasing an additional 1,009 shares during the period. Humankind Investments LLC's holdings in Amgen were worth $1,560,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in AMGN. Talbot Financial LLC raised its holdings in Amgen by 5.6% in the 4th quarter. Talbot Financial LLC now owns 42,791 shares of the medical research company's stock worth $11,153,000 after purchasing an additional 2,274 shares in the last quarter. Ascent Wealth Partners LLC grew its holdings in shares of Amgen by 0.7% during the fourth quarter. Ascent Wealth Partners LLC now owns 9,024 shares of the medical research company's stock valued at $2,352,000 after buying an additional 64 shares during the last quarter. ICICI Prudential Asset Management Co Ltd increased its holdings in shares of Amgen by 242.2% in the 4th quarter. ICICI Prudential Asset Management Co Ltd now owns 23,999 shares of the medical research company's stock worth $6,255,000 after purchasing an additional 16,985 shares in the last quarter. PFW Advisors LLC bought a new position in Amgen during the 4th quarter valued at about $1,105,000. Finally, Fisher Asset Management LLC boosted its holdings in Amgen by 285.4% in the fourth quarter. Fisher Asset Management LLC now owns 394,489 shares of the medical research company's stock worth $102,820,000 after purchasing an additional 292,137 shares during the last quarter. Hedge funds and other institutional investors own 76.50% of the company's stock.

Insider Activity at Amgen

In other Amgen news, EVP David M. Reese sold 8,711 shares of Amgen stock in a transaction that occurred on Wednesday, February 19th. The shares were sold at an average price of $293.22, for a total transaction of $2,554,239.42. Following the transaction, the executive vice president now directly owns 62,147 shares in the company, valued at approximately $18,222,743.34. The trade was a 12.29% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 0.76% of the company's stock.

Analysts Set New Price Targets

Several analysts recently issued reports on the stock. Johnson Rice set a $294.00 target price on shares of Amgen in a research report on Wednesday, March 5th. Mizuho boosted their target price on shares of Amgen from $235.00 to $280.00 and gave the stock a "neutral" rating in a report on Wednesday, May 7th. Erste Group Bank cut Amgen from a "strong-buy" rating to a "hold" rating in a report on Thursday, May 8th. Wells Fargo & Company restated an "equal weight" rating on shares of Amgen in a report on Wednesday, February 5th. Finally, Bank of America boosted their price objective on shares of Amgen from $275.00 to $294.00 and gave the company an "underperform" rating in a research report on Wednesday, March 5th. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Amgen currently has a consensus rating of "Hold" and a consensus price target of $310.23.

Amgen Stock Down 1.6%

Shares of NASDAQ:AMGN traded down $4.31 during mid-day trading on Tuesday, hitting $270.45. 2,655,241 shares of the company traded hands, compared to its average volume of 2,776,943. The firm has a market cap of $145.42 billion, a P/E ratio of 35.82, a PEG ratio of 2.63 and a beta of 0.51. The firm's 50 day simple moving average is $294.29 and its 200 day simple moving average is $289.08. The company has a debt-to-equity ratio of 9.62, a quick ratio of 0.95 and a current ratio of 1.26. Amgen Inc. has a 52-week low of $253.30 and a 52-week high of $346.85.

Amgen (NASDAQ:AMGN - Get Free Report) last issued its earnings results on Thursday, May 1st. The medical research company reported $4.90 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $4.18 by $0.72. The business had revenue of $8.15 billion for the quarter, compared to analyst estimates of $8.05 billion. Amgen had a net margin of 12.24% and a return on equity of 176.32%. The company's revenue for the quarter was up 9.4% on a year-over-year basis. During the same quarter in the prior year, the business posted $3.96 EPS. On average, equities analysts anticipate that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Friday, May 16th will be given a $2.38 dividend. The ex-dividend date is Friday, May 16th. This represents a $9.52 dividend on an annualized basis and a yield of 3.52%. Amgen's dividend payout ratio (DPR) is 86.86%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.